|
Hypobetalipoproteinemia, Familial, 2
|
0.400 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Hypobetalipoproteinemia, Familial, 2
|
0.400 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Hypercholesterolemia
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Hypotriglyceridemia
|
0.110 |
AlteredExpression
|
disease |
BEFREE |
Angptl3-deficient mice also displayed hypotriglyceridemia with elevated PHP LPL activity, but these mice showed a greater effect in the fed state.
|
16081640 |
2005 |
|
Hypotriglyceridemia
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ANGPTL3 has been demonstrated as a promising target in the pharmacological management of atherosclerosis.
|
31223079 |
2019 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Antisense oligonucleotide and monoclonal antibody-based inactivation of ANGPTL3 reduce plasma triglyceride and LDL-C levels in human volunteers and suppress atherosclerosis in mouse models.
|
30893111 |
2019 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulating evidences have revealed that ANGPTL3 plays a critical role in both biological processes, such as lipid metabolism, angiogenesis and haematopoietic function and pathological changes, including atherosclerosis, carcinogenesis, nephrotic syndrome, diabetes, liver diseases and so on.
|
30615486 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ANGPTL3 has been demonstrated as a promising target in the pharmacological management of atherosclerosis.
|
31223079 |
2019 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulating evidences have revealed that ANGPTL3 plays a critical role in both biological processes, such as lipid metabolism, angiogenesis and haematopoietic function and pathological changes, including atherosclerosis, carcinogenesis, nephrotic syndrome, diabetes, liver diseases and so on.
|
30615486 |
2019 |
|
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Antisense oligonucleotide and monoclonal antibody-based inactivation of ANGPTL3 reduce plasma triglyceride and LDL-C levels in human volunteers and suppress atherosclerosis in mouse models.
|
30893111 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Objective- Loss-of-function (LOF) variants in the ANGPTL3 (angiopoietin-like protein 3) have been associated with low levels of plasma lipoproteins and decreased coronary artery disease risk.
|
30816800 |
2019 |
|
Coronary Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of loss-of-function variants in ANGPTL3 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and LDL-C, while carriers of loss-of-function variants in ANGPTL4 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and increased HDL-C.
|
30893111 |
2019 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Objective- Loss-of-function (LOF) variants in the ANGPTL3 (angiopoietin-like protein 3) have been associated with low levels of plasma lipoproteins and decreased coronary artery disease risk.
|
30816800 |
2019 |
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of loss-of-function variants in ANGPTL3 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and LDL-C, while carriers of loss-of-function variants in ANGPTL4 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and increased HDL-C.
|
30893111 |
2019 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Objective- Loss-of-function (LOF) variants in the ANGPTL3 (angiopoietin-like protein 3) have been associated with low levels of plasma lipoproteins and decreased coronary artery disease risk.
|
30816800 |
2019 |
|
Coronary Artery Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of loss-of-function variants in ANGPTL3 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and LDL-C, while carriers of loss-of-function variants in ANGPTL4 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and increased HDL-C.
|
30893111 |
2019 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
|
29334984 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiopoietin Like protein 3 (ANGPTL3) is at present considered as a central molecular target for therapy designed to reduce atherogenic lipids and atherosclerosis.
|
30086775 |
2018 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pilot clinical trials with long acting anti-PCSK9 or anti-ANGPTL-3 oligonucleotides have yielded very promising results, so that their use as "vaccines" against atherosclerosis has been suggested in the future.
|
29498010 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our objective is to review the role of these agents in the management of patients at high ACVD risk and introduce new and (re)-emerging drugs targeting atherogenic lipoproteins such as LDL (inclisiran, bempedoic acid, etc.), remnant-like particles (fibrates, volanesorsen, and angiopoietin-like protein-3 (ANGPTL3) inhibitors), and lipoprotein(a) (AKCEA-APO[A]L<sub>RX</sub> ).
|
29737015 |
2018 |
|
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
|
29334984 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pilot clinical trials with long acting anti-PCSK9 or anti-ANGPTL-3 oligonucleotides have yielded very promising results, so that their use as "vaccines" against atherosclerosis has been suggested in the future.
|
29498010 |
2018 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiopoietin Like protein 3 (ANGPTL3) is at present considered as a central molecular target for therapy designed to reduce atherogenic lipids and atherosclerosis.
|
30086775 |
2018 |